Association between alpha-1-antichymotrypsin polymorphism and susceptibility to chronic obstructive pulmonary disease

European Journal of Clinical Investigation

Volumn 30, Issue 6, 2000, Pages 543-548

  Ishii, T ^b   Matsuse, T ^c   Teramoto, S ^b   Matsui, H ^b   Hosoi, T ^b   Fukuchi, Y ^a   Ouchi, Y ^b  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

Author keywords

Alpha 1 antichymotrypsin; Chronic obstructive pulmonary disease; Polymorphism

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; METHYLXANTHINE; PREDNISOLONE; SIGNAL PEPTIDE;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CONTROLLED STUDY; DISEASE PREDISPOSITION; EXON; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOTE; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADULT; ALANINE; ALLELES; ALPHA 1-ANTICHYMOTRYPSIN; AMINO ACID SUBSTITUTION; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; LUNG DISEASES, OBSTRUCTIVE; MALE; POLYMORPHISM, GENETIC; PROLINE; PROTEIN SORTING SIGNALS;

EID: 0034073016     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2000.00655.x     Document Type: Article

References (21)

1. 1 Murray CJL, Lopez AD. Evidence-based health policy-lessons from the global burden of disease study. Science 1996;274:740-3.
2. 2 Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J 1977;1:1645-8.
3. 3 Bascom R. Differential susceptibility to tobacco smoke: possible mechanisms. Pharmacogenetics 1991;1:102-6.
4. 4 Robin ED. Summary: Symposium on Pulmonary Emphysema and Proteolysis. In: Mittman C, editors. Pulmonary Emphysema and Proteolysis. New York: Academic Press; 1972. p.527-37.
5. 5 Church DF, Pryor WA. Free radical chemistry of cigarette smoke and its toxicological implications. Environ Health Perspect 1985;64:111-26.
6. 6 Sandford AJ, Weir TD, Pare PD. Genetic risk factors for chronic obstructive pulmonary disease. Eur Respir J 1997;10:1380-91.
7. 7 Silverman EK, Chapman HA, Drazen JM, Weiss ST, Rosner B et al. Genetic epidemiology of severe, early-onset chronic obstructive pulmonary disease. risk to relatives for airflow obstruction and chronic bronchitis. Am J Respir Crit Care Med 1998;157:1770-8.
8. 8 Nagareda T, Takeda M, Kojima K, Tanaka A, Terada N et al. Alpha-1 antichymotrypsin is increased in human alveolar macrophages by phorbol myristate acetate or lipopolysaccharide and released from these activated macrophages by glucocorticoid. J Pathol 1991;165:319-23.
9. 9 Cichy J, Potempa J, Chawla RK, Travis J. Stimulatroy effect of inflammatory cytokines on alpha 1-antichymotrypsin expression in human lung-derived epithelial cells. J Clin Invest 1995;95:2729-33.
10. 10 Poller W, Faber J-P, Weidinger S, Tief K, Scholz S et al. A leucine-to-proline substitution causes a defective alpha-1-antichymotrypsin allele associated with familial obstructive lung disease. Genomics 1993;17:740-3.
11. 11 Faber JP, Poller W, Olek K, Baumann U, Carlson J et al. The molecular basis of alpha 1-antichymotrypsin deficiency in a heterozygote with liver and lung disease. J Hepatol 1993;18:313-21.
12. 12 Siafakas NM, Vermeire P, Pride NB, Paoletti P, Gibson J et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Resp J 1995;8:1398-420.
13. 13 Sandford AJ, Chagani T, Weir TD, Pare PD. Alpha-1-antichymotrypsin mutations in patients with chronic obstructive pulmonary disease. Dis Markers 1998;13:257-60.
14. 14 Takagi M, Konttinen YT, Santavirta S, Kangaspunta P, Suda A, Rokkanen P. Cathepsin G and alpha 1-antichymotrypsin in the local host reaction to loosening of total hip prosteses. J Bone Joint Sur Am 1995;77:16-25.
15. 15 Yoshizawa T, Yamakawa-Kobayashi K, Hamaguchi H, Shoji S. Alpha-1 antichymotrypsin polymorphism in Japanese cases of Alzheimer's disease. J Neural Sci 1997;152:136-9.
16. 16 Cantlay AM, Lamb D, Gillooly M, Norrman J, Morrison D et al. Association between the CYP1A1 gene polymorphism and susceptibility to emphysema and lung cancer. J Clin Mol Pathol 1995;48:M210-4.
17. 17 Smith CAD, Harrison DJ. Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility to emphysema. Lancet 1997;350:630-3.
18. 18 Harrison DJ, Cantlay AM, Rae F, Lamb D, Smith CA. Frequency of glutathione S-transferase M1 deletion in smokers with emphysema and lung cancer. Human Exp Toxicol 1997;17:356-60.
19. 19 Huang S-L, Su C-H, Chang S-C. Tumour necrosis factor-alpha gene polymorphism in chronic bronchitis. Am J Respir Crit Care Med 1997;156:1436-9.
20. 20 Samilchuk EI, Chuchalin AG. Mis-sense mutation of alpha-1 antichymotrypsin gene and chronic lung disease. Lancet 1993;342:624.
21. 21 Harley CA, Holt JA, Turner R, Tipper DJ. Transmembrane protein insertion orientation in yeast depends on the charge difference across transmembrane segments, their total hydrophobicity, and its distribution. J Biol Chem 1998;273:24963-71.